http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9725032-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_86a4bb08e39c3c2f291f811e60581026 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-482 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-23 |
| filingDate | 1997-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24d063f248ce26e22c472f7de5580adb |
| publicationDate | 1997-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-9725032-A3 |
| titleOfInvention | Monoglyceride compositions and their use against helicobacter |
| abstract | Disclosed are compositions comprising GML (Glycerol monolaurate), as active ingredient for killing Gram negative bacteria of the genus Helicobacter. For eradiction of H. pylori colonization or treatment of infections or other disease states resulting from H. pylori colonization, the GML composition may be administered in connection with another pharmaceutically active substance useful for treating gastrointestinal disorders such as a bismuth salt, e.g., bismuth subcitrate or bismuth subsalicylate, cimetidine, ranitidine, omeprazole, lansoprazole, antacids, urease inhibitors or combinations thereof. The invention also concerns methods of treatment comprising the administration of mucolytic agents and compositions of GML. Mucolytic agents reduce or eliminate the negative effects of mucus on the action of the GML antibacterial agent and allow the GML to act locally at the sites of infection present in the mucosal epithelia. Mucolytic agents decrease the viscosity and disrupt the integrity of the mucus by various mechanisms. Mucolytic sulfhydryl compounds such as N-alkyl-cysteines, Penicillamine, N-(2-mercaptopropionyl)- glycine and WR2721 (the thiophosphate derivative of mercaptoethyl-1,3-diaminopropane) reduce disulfide bridges of the mucin matrix. The mucus may also be disrupted by exposure to hydrolytic enzymes such as glycohydrolases and proteinases, which digest the mucin, and nucleases. In particular, the proteinase, pronase, is useful for disrupting the mucin matrix. |
| priorityDate | 1996-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 51.